EGFR and glioblastoma: To test whether this is also true for the newly generated NKAB-EGFR molecule, EGFR-positive T98G glioblastoma cells were co-cultured with NKAR-NK-92 and NKAR_RD-IL15-NK-92 cells for 3 h at an E/T ratio of 5:1 in the absence or presence of increasing concentrations of purified NKAB-EGFR antibody, before the specific lysis of target cells was determined by flow cytometry.